Abstract
Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies.
However, the clinical implications of phlebotomy requirement under hydroxyurea therapy are unknown. For such purpose, need of additional phlebotomies during the first 5 years of hydroxyurea therapy was evaluated in 533 patients with polycythemia vera. Patients requiring 3 or more phlebotomies per year (n=85, 16%) showed a worse hematocrit control than those requiring 2 or less phlebotomies per year (n=448, 84%). There were no significant differences among the two study groups regarding leukocyte and platelet counts. Patients requiring 3 or more phlebotomies per year received significantly higher doses of hydroxyurea than the remainder. A significant higher rate of thrombosis was found in patients treated with hydroxyurea plus 3 or more phlebotomies per year compared to hydroxyurea with 0-2 phlebotomies per year (20.5% versus 5.3% at 3 years, p<0.0001). In multivariate analysis, independent risk factors for thrombosis were phlebotomy dependency (HR: 3.3, 95%CI: 1.5-6.9, p=0.002) and thrombosis at diagnosis (HR: 4.7, 95%CI: 2.3-9.8, p<0.0001). The proportion of patients fulfilling the European Leukemia Net criteria of resistance/intolerance to hydroxyurea was significantly higher in the group requiring 3 or more phlebotomies per year (18.7% versus 7.1%, p=0.001) mainly due to extrahematological toxicity. In conclusion, phlebotomy requirement under hydroxyurea therapy identifies a subset of patients with increased proliferation of polycythemia vera and higher risk of thrombosis.
Introduction
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by a high rate of thrombosis and bleeding (1, 2) . In the majority of patients, the disease is caused by the acquisition of mutations in the JAK2 gene resulting in an increased red cell mass and, frequently, in concomitant leukocytosis and thrombocytosis (3) . The hyperviscosity resulting from red cell expansion has a central role in the pathogenesis of thrombosis in PV, whereas functional abnormalities of platelets and leukocytes have more recently been proposed as potential contributing factors. (4-6).
Control of symptoms and prevention of thrombosis and bleeding are the main objectives of treatment in PV (7) . For such purpose, management with phlebotomies and/or cytoreductive therapy is adopted according to risk of thrombosis and patient characteristics. When cytoreduction is indicated, hydroxyurea (HU) is the first-line therapy most commonly employed. Patients receiving HU are targeted to maintain the hematocrit (Hct) below 45%, since Hct control below 45% has been associated with a lower rate of thrombosis in both observational studies and randomized clinical trials (4, 8) . However, in daily clinical practice, a proportion of patients cannot adequately control the Hct with HU alone, due to treatment side-effects or lack of response, and therefore require the concomitant use of phlebotomies for such purpose.
The aim of the present study was to assess if PV patients treated with HU requiring frequent phlebotomies have the same risk of thrombosis than those managed mainly with HU alone.
Methods

Study design
The Spanish Registry of Polycythemia Vera is a live observational study including, by February 2016, 1353 patients in which baseline characteristics, therapies and complications during follow-up are periodically updated. From this cohort, a total of 533 patients treated with HU with available data regarding hematological values, phlebotomy requirements and HU dose were included for the present study. All patients included in the study were diagnosed after year 2000. In every case, the diagnosis of PV was reassessed using the criteria of the World Health Organization (9) . The indication of HU was decided according to the criterion of the attending hematologist on the basis of the clinical guidelines and prevailing recommendations at that time. The treatment objective was to achieve Hct control below 45% without the need of phlebotomies. For such purpose, HU dose titration was performed according to individual clinical practice and patient characteristics. Supplemental phlebotomies were performed in those patients in whom the Hct was not controlled with Hu alone. In general, the policy of centers was to increase the HU dose to achieve the Hct control reserving phlebotomies as a complementary therapy. Requirement of > 3 phlebotomies was selected for categorization of the study groups due to its prognostic value and for its clinical relevance since patients requiring 3 or more phlebotomies per year require phlebotomies in the majority of visits.
The primary outcome of the study was time to first thrombotic event from HU start.
The duration of the study was 60 months after Hu start. Patients were censored at last visit, at time of HU discontinuation or at 60 months if they complete the study period. Secondary end-points included probability of bleeding (major or minor) while on treatment with HU, Hct response, CHR and probability of resistance/intolerance to HU. Thrombosis was The majority of patients achieved a stable Hct < 45% during the study period ( Figure 1A ). Overall, 304 (57%) patients required one or more phlebotomies at any time during the study. A total of 85 (16%) patients received three or more phlebotomies per year (median 4; range: 3-23). The remaining patients were included in the HU with 0-2 PHL per year group, in which the phlebotomy requirements were significantly lower (median number of phlebotomies per year 0; range: 0-2). Phlebotomy requirements during followup in the two study groups are shown in table 2.
As shown in figure 1B , the group of patients requiring 3 or more PHL per year had an inadequate Hct control, with the Hct levels being significantly higher than those requiring 0-2 PHL per year. Leukocyte counts were slightly higher in the HU with 3 and more PHL patients, but the differences were not statistically significant ( figure 1C ).
Regarding platelet counts, both groups of patients presented similar values, mostly within the normal range ( figure 1D ).
Hematocrit response and CHR at any time point was achieved in 69% and 55% of patients, respectively. However, only 51% and 34% of the total patients had a sustained response in hematocrit and CHR, respectively. Hematocrit response and CHR at different time points in the two study groups are shown in table 2. The proportion of patients achieving either Hct response or CHR was significantly lower in the group of patients requiring HU and 3 or more PHL per year. Patients requiring 3 or more PHL per year were treated with significantly higher doses of HU than the remainder. There was a trend to a progressive increase of the HU dose along the follow-up in patients with frequent phlebotomy requirements (table 2).
A total of 108 (20%) patients stopped HU during the study period. Reported reasons for discontinuation were: toxicity n=63, absence of response n=11, bleeding n=4, myeloid transformation n=1, chemotherapy for second neoplasia n= 4, other n=13, not available n=12. Resistance/intolerance to HU according to ELN criteria was observed in 51 (10%) patients. The proportion of patients fulfilling each one of definition criteria were: need for phlebotomies despite 2 g/day of HU n=8 (1.5%), uncontrolled myeloproliferation n=3 (0.6%), failure to reduce massive splenomegaly n=0, cytopenia at the lowest dose of HU to achieve a response n=6 (1.1%), extrahematological toxicity n=35 (6.6%). The 3-year probability of resistance/intolerance to HU was significantly higher in patients requiring 3 or more PHL per year than in those with 0-2 PHL per year (18.7% versus 7.1%, p=0.001, figure 2).
Thrombosis and bleeding
A total of 36 thrombotic events (22 arterial, 14 venous) were recorded resulting in a 3 and 5-year probability of thrombosis of 6.9% and 11%, respectively. Type of thrombotic events according to study groups are shown in table 3. The probability of thrombosis was significantly higher in patients treated with HU and 3 or more PHL per year than in those treated with HU and 0-2 PHL per year (20.5% versus 5.3% at 3 years, p<0.0001, figure 3 ).
Hematocrit response and CHR status at month 6, 12, 18, 24, 36, 48 or 60 was not associated with a different rate of thrombosis. Patients with sustained hematocrit response or sustained CHR experienced similar rate of thrombosis than those with intermittent or absence of response. Other variables associated with a higher or a tendency towards a higher probability of thrombosis were male gender (p=0.05), presence of either diabetes mellitus, active smoking, arterial hypertension or hypercholesterolemia (p=0.06), thrombosis prior to PV diagnosis (p=0.07), thrombosis at PV diagnosis (p<0.0001), and leukocyte count at time of HU start > 10x10 9 /L (p=0.09). Age and platelet count at time of HU start were not associated with a higher probability of thrombosis.
Multivariate analysis including sex, cardiovascular risk factors, thrombosis at PV diagnosis and need for phlebotomies is shown in table 4. Patients treated with HU and 3 or more PHL per year had a 3.3 fold increase (95% CI: 1.5-6.9) in the risk of thrombosis.
Additionally, patients with thrombosis at PV diagnosis showed the highest risk for developing thrombosis under HU therapy. When sustained hematocrit response or sustained CHR were included in the multivariate model, phlebotomy requirements retained its prognostic value while hematocrit response or CHR were not associated with the risk of thrombosis.
Twenty-five bleeding events (6 major, 19 minor) were registered, resulting in a 3-and 5-year probability of 4.4% and 6.7%, respectively. The 3-year probability of bleeding was higher in the group of patients requiring 3 or more PHL per year than in the remainder, but the difference was not statistically significant (7.4% versus 4.2%, respectively, p=0.4, figure 4 ). In multivariate analysis, therapy with HU and 3 or more PHL per year was not associated with a higher risk of bleeding (HR: 5.5, 95%CI: 0.5-5.1, p=0.4) after adjusting for treatment with antiplatelet agents or oral anticoagulants.
Discussion
HU is the cytoreductive therapy most often used in PV, however, few studies have evaluated in detail the optimal management of such agent in clinical practice. In particular, no studies have examined if the need of phlebotomy under treatment with HU has any impact on the major complications of the disease. In the present study, we have shown that patients with PV treated with HU requiring 3 or more phlebotomies per year have an increased risk of thrombosis and develop more frequently resistance/intolerance to HU.
According to current recommendations, PV patients under cytoreduction are targeted to maintain the Hct < 45% (7, 11) . In this regard, most patients in the present study were able to keep the hematocrit below 45%, with the values observed being superimposed to those reported in the higher intensity group of the CytoPV study (8) . Moreover, our cohort of patients received HU dosages that were comparable or even higher than those previously reported by others (8, 12 ). However, we identified a subgroup of patients requiring a higher intensity of treatment consisting of both higher HU doses and higher number of phlebotomies. These patients, representing 16% of the total series, experienced a higher rate of thrombosis and, on multivariate analysis, PHL requirement while on HU therapy was an independent risk factor for thrombosis. This finding emphasizes the importance of an adequate HU dose adjustment to maintain the Hct below 45% without significant fluctuations. Alternatively, if HU dose cannot be increased, more frequent phlebotomies or change to second line therapy is advised.
It could be argued that the need for phlebotomy could result from a lower intensity of cytoreductive treatment. In our series, however, the situation was just the opposite since patients with high phlebotomy requirements received significant higher doses of HU than those treated with HU alone. This finding suggest that this subgroup of patients have a disease with an increased proliferative capacity requiring a higher treatment intensity to achieve the Hct control. In this sense, the observation that the hematocrit values prior to HU start were also significantly higher in the group of patients treated with HU and 3 or more PHL per year supports this possibility. An alternative explanation would be a lower individual sensitivity to treatment with HU that could result in worse control of the disease when conventional doses of HU are used.
Although up to 16% of patients required 3 or more phlebotomies per year to control the disease, the majority of these patients could not be classified as resistant to HU since the dose intensity of 2 g per day was not reached. In fact, only 1.5% of patients met the Hct resistance criterion defined by ELN as reported in previous studies (12-13). Nevertheless, a higher rate of resistance/intolerance to HU was observed in patients requiring 3 or more PHL per year mainly due to more frequent extrahematological toxicity. A finding that could be explained by the higher HU doses employed in the group requiring supplemental phlebotomies. This features illustrate the difficult application of ELN resistance criteria in the daily clinical practice. In this sense, the concept of maximum tolerated dose of HU to maintain the Hct below 45% instead of a dose > 2 g per day may be more appropriate to consider a patient as resistant to HU (14).
An intriguing finding of the present work was the absence of a clear association between the Hct response and the risk of thrombosis. This feature does not mean at all that patients should not be controlled according to the well-established criteria of response. In fact, patients treated with HU plus 3 or more PHL per year had a worse hematocrit control throughout the study and therefore a lower response rate. However, classification of patients based on the phlebotomy requirement seems to better discriminate those patients at high risk of thrombosis than the categorization of responders / non-responders. Although our results suggest that the thrombotic risk of patients requiring frequent phlebotomies is related to an inadequate Hct control, a detrimental effect of frequent phlebotomies by itself could not be discarded. On the other hand, we have observed no significant differences in the leukocyte and platelet counts during treatment with HU between the two study groups, suggesting a predominant role of the increased red cell mass in the thrombotic risk of PV.
The main limitation of the present study is its retrospective design. The absence of a protocol including a standardized titration of the HU dose or the indication for phlebotomy can result in significant bias affecting the validity of the observed findings. On the other hand, the definition of study groups according to requirement of 3 or more phlebotomies per year may also be criticized. The only way to solve these biases would be conducting a prospective study with a pre-established definition of study groups including a precise protocol of both dose titration and indication for phlebotomy. Despite the aforementioned limitations, the detailed analysis of the treatment received by patients included in registries as the present one is an excellent opportunity to evaluate and improve the clinical practice in a real scenario, which is often difficult to carry out from clinical trials.
In conclusion, PV patients treated with HU requiring 3 or more PHL per year have a higher risk of thrombotic complications. These findings highlight the importance of intime dose adjustment adapted to the proliferative activity of the disease. 
